JP2023520929A5 - - Google Patents

Info

Publication number
JP2023520929A5
JP2023520929A5 JP2022561484A JP2022561484A JP2023520929A5 JP 2023520929 A5 JP2023520929 A5 JP 2023520929A5 JP 2022561484 A JP2022561484 A JP 2022561484A JP 2022561484 A JP2022561484 A JP 2022561484A JP 2023520929 A5 JP2023520929 A5 JP 2023520929A5
Authority
JP
Japan
Prior art keywords
composition according
optionally
cov
sars
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022561484A
Other languages
English (en)
Japanese (ja)
Other versions
JP7840570B2 (ja
JP2023520929A (ja
Filing date
Publication date
Priority claimed from US16/875,487 external-priority patent/US11116737B1/en
Application filed filed Critical
Priority claimed from PCT/US2021/026588 external-priority patent/WO2021207606A1/en
Publication of JP2023520929A publication Critical patent/JP2023520929A/ja
Publication of JP2023520929A5 publication Critical patent/JP2023520929A5/ja
Priority to JP2026018466A priority Critical patent/JP2026077677A/ja
Application granted granted Critical
Publication of JP7840570B2 publication Critical patent/JP7840570B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022561484A 2020-04-10 2021-04-09 コロナウイルス感染症の処置のための方法 Active JP7840570B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026018466A JP2026077677A (ja) 2020-04-10 2026-02-06 コロナウイルス感染症の処置のための方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063008624P 2020-04-10 2020-04-10
US63/008,624 2020-04-10
US202063023021P 2020-05-11 2020-05-11
US63/023,021 2020-05-11
US16/875,487 2020-05-15
US16/875,487 US11116737B1 (en) 2020-04-10 2020-05-15 Methods of using probenecid for treatment of coronavirus infections
EP20202059.0A EP3892269B1 (en) 2020-04-10 2020-10-15 Probenecid for treating coronavirus infections
EP20202059.0 2020-10-15
US202163151551P 2021-02-19 2021-02-19
US63/151,551 2021-02-19
PCT/US2021/026588 WO2021207606A1 (en) 2020-04-10 2021-04-09 Methods for treatment of coronavirus infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026018466A Division JP2026077677A (ja) 2020-04-10 2026-02-06 コロナウイルス感染症の処置のための方法

Publications (3)

Publication Number Publication Date
JP2023520929A JP2023520929A (ja) 2023-05-22
JP2023520929A5 true JP2023520929A5 (cg-RX-API-DMAC7.html) 2024-04-16
JP7840570B2 JP7840570B2 (ja) 2026-04-06

Family

ID=78023981

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022561484A Active JP7840570B2 (ja) 2020-04-10 2021-04-09 コロナウイルス感染症の処置のための方法
JP2026018466A Pending JP2026077677A (ja) 2020-04-10 2026-02-06 コロナウイルス感染症の処置のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026018466A Pending JP2026077677A (ja) 2020-04-10 2026-02-06 コロナウイルス感染症の処置のための方法

Country Status (6)

Country Link
EP (1) EP4132503B1 (cg-RX-API-DMAC7.html)
JP (2) JP7840570B2 (cg-RX-API-DMAC7.html)
CN (1) CN116075298B (cg-RX-API-DMAC7.html)
AU (1) AU2021254262A1 (cg-RX-API-DMAC7.html)
ES (1) ES3074777T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021207606A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230302031A1 (en) * 2020-06-02 2023-09-28 Institut Gustave-Roussy Modulators Of Purinergic Receptors and Related Immune Checkpoint For Treating Acute Respiratory Distress Syndrome
AU2022309236A1 (en) * 2021-07-06 2024-01-25 University Of Georgia Research Foundation, Inc. Compositions and methods for treating and preventing viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1649053A4 (en) * 2003-06-18 2006-10-18 Chinese Nat Human Genome Ct Sh CHARACTERIZATION OF THE EARLY LEVELS OF THE VIRUS OF HEAVY ACUTE RESPIRATORY SYNDROME (SARS) AND USES THEREOF
WO2011127019A2 (en) * 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
WO2011146527A2 (en) 2010-05-17 2011-11-24 Zirus, Inc. Mammalian genes involved in infection
US11554112B2 (en) * 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
HUE062848T2 (hu) * 2018-09-14 2023-12-28 Enlitisa Shanghai Pharmaceutical Co Ltd Montelukaszt és peptidek konjugátumai
AU2020289560A1 (en) * 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections

Similar Documents

Publication Publication Date Title
JP2023522010A5 (cg-RX-API-DMAC7.html)
JP2023535744A5 (cg-RX-API-DMAC7.html)
US20230201497A1 (en) Method for pulsatile delivery of a gaseous drug
JP2023520323A5 (cg-RX-API-DMAC7.html)
EA022840B1 (ru) Фармацевтическая композиция, набор, их применение и способ профилактики и лечения симптома, состояния или заболевания, связанного с инфекцией вируса гриппа
US20220387455A1 (en) Treatment of moderate to severe influenza
CN111658779A (zh) 治疗新型冠状病毒肺炎的联合用药物
JP2024504225A5 (cg-RX-API-DMAC7.html)
JP2023520591A5 (cg-RX-API-DMAC7.html)
JP2022553888A5 (cg-RX-API-DMAC7.html)
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物
FI4199922T3 (fi) (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa
WO2022199049A1 (zh) 乌司他丁在制备治疗新型冠状病毒肺炎药物中的用途
JP2023539847A5 (cg-RX-API-DMAC7.html)
JP2024543259A5 (cg-RX-API-DMAC7.html)
CN115884770A (zh) 治疗冠状病毒感染的联用药物及治疗方法
CN115867288A (zh) 用于治疗呼吸系统病症的组合物
Van Wyk The common cold and influenza: colds & flu
US12171732B2 (en) Compositions and use of N-chlorotaurine for treatment and prevention of respiratory infections
JP2024537906A5 (cg-RX-API-DMAC7.html)
KR20250053864A (ko) 호흡기 감염을 치료하기 위한 약제학적 건조 분말 조성물 및 방법
CN116531491A (zh) 一种干扰素α1b在制备防治甲型流感病毒感染引发的疾病的药物中的用途
BR102020005172A2 (pt) Zinco como medicamento antiviral eficaz para a família coronaviridae e seus genomas, gêneros e grupos
HK40096303A (en) Bupropion and dextromethorphan for reduction of suicide risk in depression patients